Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types
Natalia Gorbokon, Katharina Teljuk, Nina Schraps, Maximilian Lennartz, Sebastian Dwertmann Rico, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Christoph Fraune, Andreas M Luebke, Anne Menz, Ria Schlichter, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Stefan Steurer, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Thilo Hackert, Faik G. Uzunoglu, Christian Bernreuther, Martina Kluth · 2026
Read Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types by Natalia Gorbokon, Katharina Teljuk, Nina Schraps, Maximilian Lennartz, Sebastian Dwertmann Rico, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Christoph Fraune, Andreas M Luebke, Anne Menz, Ria Schlichter, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Stefan Steurer, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Thilo Hackert, Faik G. Uzunoglu, Christian Bernreuther, Martina Kluth (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13312514.txt.
Description
Natalia Gorbokon and a large team report a 2026 tissue microarray study measuring how often cancers lose part of chromosome 9p21. Losing both copies of this region strips tumors of the MTAP protein and exposes weaknesses that certain drugs can exploit, so knowing which cancers carry the deletion matters for treatment planning.
The array held samples from 125 tumor types, and fluorescence testing succeeded on 4,999 tumors. Overall, 10.7 percent carried a one-copy deletion and 7.4 percent had lost both copies. Complete loss clustered in mesothelioma, pancreatic ductal adenocarcinoma, and bladder urothelial carcinoma, while single-copy loss led in squamous cell carcinoma, leiomyosarcoma, and esophageal adenocarcinoma. Staining confirmed MTAP and p16 protein vanished when both copies were gone and faded with one. The authors supply prevalence figures to guide targeted therapy trials.
Catalog record
| CREATOR | Natalia Gorbokon, Katharina Teljuk, Nina Schraps, Maximilian Lennartz, Sebastian Dwertmann Rico, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Christoph Fraune, Andreas M Luebke, Anne Menz, Ria Schlichter, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Stefan Steurer, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Thilo Hackert, Faik G. Uzunoglu, Christian Bernreuther, Martina Kluth |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31012 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |